World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025
Award Badge
Medicine
USA
2026

D-Index & Metrics

Best Scientists

D-Index
260
Citations
320383
World Ranking
36
National Ranking
24

Medicine

D-Index
265
Citations
332965
World Ranking
21
National Ranking
16

Research.com Recognitions

  • 2026 - Research.com Medicine in United States Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Medicine in United States Leader Award
  • 2023 - Research.com Medicine in United States Leader Award
  • 2012 - Fellow of the American Association for the Advancement of Science (AAAS)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Hagop M. Kantarjian is affiliated with The University of Texas MD Anderson Cancer Center in the United States and has contributed extensively to the field of medicine, with a primary focus on hematology. Their research encompasses genetics, public health, environmental and occupational health, molecular biology, and oncology.

The scientist's work addresses several key topics, including:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • CAR-T Cell Therapy Research
  • Hematopoietic Stem Cell Transplantation

Kantarjian has contributed to numerous publications spanning several prominent medical journals. Their frequent publication venues include:

  • Blood (62 publications)
  • American Journal of Hematology (53 publications)
  • Cancer (33 publications)
  • Blood Advances (23 publications)
  • Leukemia (22 publications)

Among recent papers authored or co-authored by Kantarjian are:

  • "Acute myeloid leukemia: current progress and future directions," 2021, Blood Cancer Journal
  • "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms," 2022, Leukemia
  • "European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia," 2020, Leukemia
  • "Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML," 2020, Blood
  • "Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes," 2021, Journal of Clinical Oncology

Frequent collaborators include:

  • Elias Jabbour
  • Farhad Ravandi
  • Tapan M. Kadia
  • Courtney D. DiNardo
  • Nicholas J. Short

Kantarjian has been recognized within the medical community as a Fellow of the American Association for the Advancement of Science (AAAS) since 2012. They are also a member of the Association of American Physicians.

Best Publications

  • Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

    Brian J. Druker;Moshe Talpaz;Debra J. Resta;Bin Peng

  • Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

    Timothy J. Ley;Christopher Miller;Li Ding;Benjamin J. Raphael

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

    Brian J. Druker;Charles L. Sawyers;Hagop M Kantarjian;Debra J. Resta

  • Revised International Prognostic Scoring System for Myelodysplastic Syndromes

    Peter L. Greenberg;Heinz Tuechler;Julie Schanz;Guillermo Sanz

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

    Moshe Talpaz;Neil P. Shah;Hagop M Kantarjian;Nicholas Donato

  • A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

    Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy

  • A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

    Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover

  • Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

    Giuseppe Saglio;Dong-Wook Kim;Surapol Issaragrisil;Gabriel Etienne

  • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

    Hagop Kantarjian;Neil P. Shah;Andreas Hochhaus;Jorge Cortes

  • Clinical effect of point mutations in myelodysplastic syndromes.

    Rafael Bejar;Kristen Stevenson;Omar Abdel-Wahab;Naomi Galili

  • Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

    Hagop M Kantarjian;Anthony Stein;Nicola Gökbuget;Adele K. Fielding

  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

    Bruce D. Cheson;Peter L. Greenberg;John M. Bennett;Bob Lowenberg

  • The biology of chronic myeloid leukemia

    Stefan Faderl;Moshe Talpaz;Zeev Estrov;Susan O'Brien

  • Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

    Hagop M Kantarjian;Francis Giles;Lydia Wunderle;Kapil Bhalla

Frequent Co-Authors

Jorge E. Cortes
Jorge E. Cortes Augusta University
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Sherry Pierce
Sherry Pierce The University of Texas MD Anderson Cancer Center
Marina Konopleva
Marina Konopleva The University of Texas MD Anderson Cancer Center
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Naval Daver
Naval Daver The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Thinking about your future in medicine? There are several online degrees and career paths to consider beyond traditional medical school. Many students are now exploring flexible programs that allow them to specialize in healthcare management, advanced nursing, pharmacy, or health information while balancing work and life commitments.

For those aiming to become leaders in healthcare settings, pursuing cheap mha programs is a smart option. These degrees can help you build managerial skills crucial for hospitals and clinics. If you're a nurse interested in climbing the professional ladder, consider dnp online programs cheap to achieve the highest level of nursing practice affordably.

Aspiring pharmacists can benefit from the flexibility of online pharmacy schools, while those drawn to health data and technology should look into an online health information management degree. Each pathway offers distinct career opportunities and suits different interests within the ever-evolving healthcare industry.

Best Scientists Citing Hagop M. Kantarjian

Trending Scientists

Recently Published Articles